Dr. Salman Ahmed
Natural products targeting the atr-chk1 signaling pathway in cancer therapy
Journal title : Biomedicine & Pharmacotherapy
Publisher : Elsevier BV
Print ISSN : 0753-3322
Page Number : 113797
Journal volume : 155
280 Views Reviews Article
Cancer is one of the most severe medical conditions in the world, causing millions of deaths each year. Chemotherapy and radiotherapy are critical treatment approaches, but both have numerous adverse health effects. Furthermore, the resistance of cancerous cells to anticancer medication leads to treatment failure. The rising burden of cancer requires novel, efficacious treatment modalities. Natural remedies offer feasible alternative options against malignancy in contrast to available synthetic medication. Selective killing of cancer cells is privileged mainstream in cancer treatment, and targeted therapy represents the new tool with the potential to pursue this aim. The discovery of innovative therapies targeting essential components of DNA damage signalling and repair pathways, such as ataxia telangiectasia mutated and Rad3-related Checkpoint kinase 1 (ATR-CHK1), has offered a possibility of significant therapeutic improvement in oncology. The activation and inhibition of this pathway account for chemopreventive and chemotherapeutic activity, respectively. Targeting this pathway can also aid in overcoming the resistance of conventional chemo- or radiotherapy. This review enlightens the anticancer role of natural products by ATR-CHK1 activation and inhibition. Additionally, these compounds have been shown to have chemotherapeutic synergistic potential when used in combination with other anticancer drugs. Ideally, this review will trigger interest in natural products targeting ATR-CHK1 and their potential efficacy and safety as cancer-lessening agents.
Article DOI & Crossmark Data
DOI : https://doi.org/10.1016/j.biopha.2022.113797
Article Subject Details
Article Keywords Details
Article File
Full Text PDFArticle References
- (1). 10.1016/S1470-2045(12)70211-5
- (2). 10.3390/ijms21165622
- (3). 10.1016/j.phymed.2019.152883
- (4). Barffour, I.K., Anti-hepatocellular carcinoma effect of an alkaloidal extract derived from zanthoxylum zanthoxyloides. 2019, University of Cape Coast.
- (5). 10.1053/j.gastro.2009.10.031
- (6). 10.1038/s41392-020-0150-x
- (7). 10.3390/cells9071665
- (8). 10.1039/C6MD00439C
- (9). 10.3390/cancers9050041
- (10). 10.1016/j.tibs.2020.11.002
- (11). 10.1016/j.pharmthera.2014.12.001
- (12). 10.3390/biom5031912
- (13). 10.1016/B978-0-12-380888-2.00003-0
- (14). 10.1017/erm.2020.3
- (15). 10.1016/j.radonc.2017.09.043
- (16). 10.1158/1078-0432.CCR-15-0479
- (17). 10.3390/cancers13040795
- (18). 10.1038/nrm.2017.67
- (19). 10.1002/ijc.28226
- (20). 10.1016/j.pharmthera.2019.107450
- (21). 10.1002/JLB.2MA0321-064R
- (22). 10.1101/gad.14.12.1439
- (23). 10.1101/gad.14.4.397
- (24). 10.1093/emboj/17.1.159
- (25). 10.1038/ncb2897
- (26). 10.1101/gad.1522607
- (27). 10.1101/cshperspect.a012716
- (28). 10.1126/science.1065521
- (29). 10.1128/MCB.02238-06
- (30). 10.1101/gad.1666208
- (31). 10.1016/j.dnarep.2005.04.001
- (32). Hussain, R.N., Radiation Biology of Uveal Melanoma. 2020: The University of Liverpool (United Kingdom).
- (33). 10.1242/jcs.035105
- (34). 10.1126/science.271.5247.353
- (35). 10.1101/gad.14.12.1448
- (36). 10.1128/MCB.00492-06
- (37). 10.1016/S1097-2765(05)00092-4
- (38). 10.1111/febs.13387
- (39). 10.1093/nar/gkr697
- (40). 10.1128/MCB.23.21.7488-7497.2003
- (41). 10.1158/1078-0432.CCR-09-1029
- (42). 10.1091/mbc.12.3.551
- (43). 10.1038/nrm2450
- (44). 10.1042/BJ20102162
- (45). 10.1016/S1535-6108(03)00048-5
- (46). 10.1016/j.dnarep.2007.02.015
- (47). 10.1158/0008-5472.CAN-11-2904
- (48). 10.1038/sj.onc.1209828
- (49). 10.1101/gad.851000
- (50). 10.1038/ncb1212
- (51). 10.1038/bjc.2011.243
- (52). 10.1158/1535-7163.MCT-08-0662
- (53). 10.1016/j.molcel.2016.12.007
- (54). 10.1016/j.molmed.2010.10.009
- (55). 10.4161/cc.10.24.18661
- (56). 10.1124/mi.11.2.11
- (57). 10.4161/cc.6.1.3699
- (58). 10.1158/1535-7163.MCT-06-0371
- (59). 10.1002/ijc.28521
- (60). 10.2174/187152012800617678
- (61). 10.1080/15384047.2015.1078021
- (62). 10.1093/nar/gkp593
- (63). George, V.C. and H. Rupasinghe, Apple flavonoids suppress carcinogen-induced DNA damage in normal human bronchial epithelial cells. Oxidative Medicine and Cellular Longevity, 2017. 2017.
- (64). 10.3892/or.2012.2170
- (65). 10.1142/S0192415X1550024X
- (66). 10.4238/2015.May.12.2
- (67). 10.3390/biom11010079
- (68). 10.1158/1535-7163.MCT-11-0921
- (69). 10.1155/2020/2543504
- (70). 10.1093/carcin/bgt240
- (71). 10.1093/carcin/bgi165
- (72). 10.1093/carcin/bgm283
- (73). 10.3892/or.2015.3871
- (74). 10.1002/ijc.30764
- (75). 10.3390/cancers13143438
- (76). 10.1097/CEJ.0b013e328353edcb
- (77). 10.1158/1535-7163.MCT-11-0921
- (78). 10.18632/oncotarget.6482
- (79). 10.1155/2020/2172740
- (80). 10.1016/j.bbrc.2005.07.097
- (81). 10.3390/cancers3011351
- (82). 10.1186/2162-3619-4-5
- (83). Demarcq, C., et al., The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells.
- (84). 10.1016/j.molonc.2014.10.013
- (85). 10.1016/j.molcel.2016.03.006
- (86). 10.1007/s11060-015-2050-4
- (87). 10.3390/cancers13040795
- (88). 10.1158/1535-7163.MCT-10-0928
- (89). 10.1517/17460441.2013.788496
- (90). 10.1038/nchembio.573
- (91). O'Carrigan, B., et al., Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. 2016, American Society of Clinical Oncology.
- (92). Plummer, E.R., et al., Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792). 2016, American Society of Clinical Oncology.
- (93). Shapiro, G., et al., Abstract CT012: phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792). 2016, AACR.
- (94). Dillon, M., et al. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. in ASCO. 2016: ASCO.
- (95). 10.1007/s00280-014-2380-5
- (96). 10.1200/JCO.2014.57.5027
- (97). 10.1097/CAD.0000000000000278
- (98). 10.1159/000448621
- (99). 10.1007/s10637-016-0368-1
- (100). 10.3390/biomedicines9101476
- (101). 10.3390/biom11010079
More Article by Dr. Salman Ahmed
The seeds of cleome viscosa are used in traditional systems of medicine for the treatment of many diseases in asia. this study evaluated fixed oil from the seeds of cleome viscosa...
Plants have been used as medicine for the treatment of diseases for thousands of years. these herbal remedies, although natural, can cause some serious damaging effects on the vita...
The current study was conducted to explore the antiemetic activity of ten aromatic medicinal plants viz., carissa carandus l. (fruits), chichorium intybus l (flowers), cinnamum tam...
Crude methanol extracts of the leaves of adenanthera pavonina l., peltoforum roxburghii l, prosopis cineraria l., and prosopis juliflora dc., were evaluated for anti-emetic activit...